Title : Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.

Pub. Date : 2016 May

PMID : 26111826






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 After switching to fingolimod (M0-12 vs M13-EOS), patients initially treated with IFN had a 50% reduction in ARR (0.40 vs 0.20), reduced MRI activity and a lower rate of brain volume loss. Fingolimod Hydrochloride interferon alpha 1 Homo sapiens
2 In a post hoc analysis, the proportion of IFN-switch patients with no evidence of disease activity increased by approximately 50% in the first year after switching to fingolimod treatment (44.3% to 66.0%). Fingolimod Hydrochloride interferon alpha 1 Homo sapiens